Cytokine Signalling Forum


Sign in   Register
  • Home
  • Publications
  • Podcasts
  • Congresses
  • Educational Videos
  • Resources
  • CSF Live
  • Contact

Publications

All ▼
(Checked) All Axial Spondyloarthritis Psoriatic Arthritis Rheumatoid Arthritis
Date of upload ▼
(Checked) Date of upload Date of publication Published 2023 Published 2022 Published 2021 Published 2020 Published 2019 Published 2018 Published 2017 Published 2016 Published 2015 Published 2014 Published pre-2014
English ▼
(Checked) English Español Français Italiano Türkçe 日本語 Português

View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.

Literature Highlights

Literature review thumbnail: PsA Literature Highlights – March 2023
View Slides

PsA Literature Highlights – March 2023

more…

Keywords:

Tofacitinib, Ustekinumab, Guselkumab, Ixekizumab, DISCOVER-1
Previous

Publications

Clear Search

Showing 1 result for “Foeldvari I”.

September 2022
Publication thumbnail: Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: A Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Trial View Slides

Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: A Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Trial

Brunner HI
,
Foeldvari I
,
Alexeeva E
,
Ayaz NA
,
Calvo Penades I
,
Kasapcopur O
,
Chasnyk VG
,
Hufnagel M
,
Żuber Z
,
Schulert G
,
Ozen S
,
Rakhimyanova A
,
Ramanan A
,
Scott C
,
Sozeri B
,
Zholobova E
,
Martin R
,
Zhu X
,
Whelan S
,
Pricop L
,
Martini A
,
Lovell D
,
Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

Ann Rheum Dis. 2022 2022 2022-222849

In the latest study by Brunner, et al. secukinumab demonstrated efficacy and safety in the JIA categories of ERA and JPsA. This phase 3 study aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA.

more…

Keywords:

  • Secukinumab,
  • Phase 3,
  • ERA,
  • JPsA
Download Slides Access via PubMed
 

Developed under the auspices of:

University of Glasgow

With sponsorship and unrestricted educational grants from:

Lilly logo Abbvie logo

Follow us on:

Twitter LinkedIn Facebook Apple Podcasts

© 2014 - 2023 | Supported by CESAS Medical. Legal | Contact | Site Map

APEX Award Winning logo
Health Awards logo